IMA NASDAQ
ImageneBio Inc
1W: -5.4%
1M: -9.8%
3M: -17.3%
YTD: -20.0%
1Y: -59.4%
3Y: -93.6%
5Y: -97.7%
$5.25
-0.40 (-7.08%)
Pre-Market: $5.53 (+0.28, +5.24%)
Weekly Expected Move ±8.8%
$5
$5
$6
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$59.2M
52W Range3.94-18
Volume14,734
Avg Volume363,331
Beta0.74
Dividend—
Analyst Ratings
Company Info
CEOKristin Yarema
Employees10
SectorHealthcare
IndustryBiotechnology
IPO Date1998-02-27
Websiteinmagenebio.com
12526 High Bluff Drive, Suite 345, San Diego, CA 92130
San Diego, CA 92130
US
San Diego, CA 92130
US
858 345 6265
About ImageneBio Inc
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably nonâdepleting antiâOX40 monoclonal antibody IMGâ007 in Phase 2b for atopic dermatitis
Latest News
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Wins Pivotal Phase III Approval, Set to Reshape the Frontline Treatment Landscape for Advanced EP-NEC
Lundbeck receives orphan drug designation in Japan for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing's disease
Kelun-Biotech Receives Investigational New Drug Approval from CDE for SKB118, a PD-1 x VEGF Bispecific Antibody
China Innovative Drug NHWD-870 Receives Breakthrough Therapy Designation, Bringing New Hope of Survival to NUT Carcinoma Patients
China Innovative Drug NHWD-870 Receives Breakthrough Therapy Designation, Bringing New Hope of Survival to NUT Carcinoma Patients
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Su Wei-guo | 0 | — | 2026-04-16 | |
| Lally Robert B | 0 | — | 2026-03-20 | |
| Lally Robert B | 25,410 | $6.20 | 2026-03-20 | |
| Yarema Kristin | A-Award | 128,100 | $6.20 | 2026-03-16 |
| Yarema Kristin | A-Award | 85,400 | — | 2026-03-16 |